ImmunoGen, a Waltham-based biotechnology company, has made significant advances in developing antibody-drug conjugates (ADCs) for cancer patients. Its portfolio includes mirvetuximab soravtansine, an ADC that targets the folate-receptor alpha (FRa) to treat platinum-resistant ovarian cancer. It also includes Pivekimab sunirine, a CD123-targeting ADC currently in Phase II clinical trial for the treatment of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The company's preclinical programs include IMGC936, a co-development with MacroGenics, Inc., and anti-FRa product candidate IMGN151. ImmunoGen has established collaborations with major players in the healthcare industry, including Roche, Amgen/Oxford BioTherapeutics, and Bayer HealthCare AG. The company has bullish prospects for the use of its innovative technology to develop cancer treatments.
ImmunoGen's ticker is IMGN
The company's shares trade on the NASDAQ stock exchange
They are based in Waltham, Massachusetts
There are 201-500 employees working at ImmunoGen
It is immunogen.com/who-we-are
ImmunoGen is in the Healthcare sector
ImmunoGen is in the Biotechnology industry
The following five companies are ImmunoGen's industry peers: